Parabilis Medicines (PBLS) Stock Price, News & Analysis

Company Overview

Parabilis Medicines Inc. is a clinical-stage biopharmaceutical company built to develop transformative medicines addressing some of the most consequential, yet historically undruggable, protein targets driving human disease. Parabilis Medicines Inc. is based in CAMBRIDGE, Mass.

Key Stats

• Today's Range: $31.06 to $33.72
• 50-Day Range: $27.31 to $41.73
• 52-Week Range: $24.51 to $42.49
• Volume: 1.17 million shs
• Average Volume: 1.01 million shs
• Market Capitalization: $4.01 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $41.67
• Consensus Rating: Moderate Buy

Parabilis Medicines Stock Analysis - MarketRank™

Parabilis Medicines scored higher than 69% of companies evaluated by MarketBeat, and ranked 224th out of 901 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Parabilis Medicines has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on 1 strong buy rating, 4 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Parabilis Medicines has a consensus price target of $41.67, representing about 28.3% upside from its current price of $32.47.

Amount of Analyst Coverage

Parabilis Medicines has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Parabilis Medicines are expected to grow in the coming year, from ($2.05) to ($1.60) per share.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

4.93% of the float of Parabilis Medicines has been sold short.

Short Interest Ratio / Days to Cover

Parabilis Medicines has a short interest ratio ("days to cover") of 13.25, which indicates bearish sentiment.

Change versus previous month

Short interest in Parabilis Medicines has recently increased by 10.41%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Parabilis Medicines does not currently pay a dividend.

Dividend Growth

Parabilis Medicines does not have a long track record of dividend growth.

News and Social Media

• Score: 3.4 / 5
• News Sentiment: 0.38

News Sentiment

Parabilis Medicines has a news sentiment score of 0.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.72 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Parabilis Medicines this week, compared to 3 articles on an average week.

Search Interest

2 people have searched for PBLS on MarketBeat in the last 30 days.

MarketBeat Follows

4 people have added Parabilis Medicines to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days.

Company Ownership

• Score: N/A
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Parabilis Medicines insiders have not sold or bought any company stock.

Percentage Held by Institutions

Parabilis Medicines has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/13/2026
• Today: 9/24/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:PBLS
• CIK: 1657677
• Web: parabilismed.com
• Phone: 617-945-9510
• Fax: N/A
• Employees: 145
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Parabilis Medicines: $41.67
• High Price Target: $45.00
• Low Price Target: $40.00
• Potential Upside/Downside: +28.3%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.71
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 123,530,000
• Free Float: N/A
• Market Cap: $4.01 billion
• Optionable: N/A
• Beta: N/A